LTC2152868I2 - Prokariotinės fenilalanino amonio liazės kompozicijos ir minėtų kompozicijų naudojimo būdai - Google Patents

Prokariotinės fenilalanino amonio liazės kompozicijos ir minėtų kompozicijų naudojimo būdai

Info

Publication number
LTC2152868I2
LTC2152868I2 LTPA2019517C LTPA2019517C LTC2152868I2 LT C2152868 I2 LTC2152868 I2 LT C2152868I2 LT PA2019517 C LTPA2019517 C LT PA2019517C LT PA2019517 C LTPA2019517 C LT PA2019517C LT C2152868 I2 LTC2152868 I2 LT C2152868I2
Authority
LT
Lithuania
Prior art keywords
compositions
methods
ammonium lyase
phenylalanine ammonium
prokaryotic phenylalanine
Prior art date
Application number
LTPA2019517C
Other languages
English (en)
Lithuanian (lt)
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39868905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2152868(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of LTPA2019517I1 publication Critical patent/LTPA2019517I1/lt
Publication of LTC2152868I2 publication Critical patent/LTC2152868I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTPA2019517C 2007-05-25 2019-10-10 Prokariotinės fenilalanino amonio liazės kompozicijos ir minėtų kompozicijų naudojimo būdai LTC2152868I2 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/807,227 US7534595B2 (en) 2006-06-12 2007-05-25 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
PCT/US2008/006661 WO2008153776A1 (en) 2007-05-25 2008-05-23 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions

Publications (2)

Publication Number Publication Date
LTPA2019517I1 LTPA2019517I1 (lt) 2019-10-25
LTC2152868I2 true LTC2152868I2 (lt) 2020-09-25

Family

ID=39868905

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2019517C LTC2152868I2 (lt) 2007-05-25 2019-10-10 Prokariotinės fenilalanino amonio liazės kompozicijos ir minėtų kompozicijų naudojimo būdai

Country Status (29)

Country Link
US (1) US7534595B2 (enExample)
EP (2) EP2152868B1 (enExample)
JP (1) JP5670183B2 (enExample)
KR (2) KR101603796B1 (enExample)
CN (1) CN101842482B (enExample)
AR (2) AR066716A1 (enExample)
AU (1) AU2008263190B2 (enExample)
BR (1) BRPI0811267B8 (enExample)
CA (1) CA2687450C (enExample)
CL (1) CL2008001497A1 (enExample)
CY (2) CY1116894T1 (enExample)
DK (1) DK2152868T3 (enExample)
EA (1) EA018443B1 (enExample)
ES (1) ES2551315T3 (enExample)
HR (1) HRP20151268T1 (enExample)
HU (2) HUE025784T2 (enExample)
IL (1) IL202132A (enExample)
LT (1) LTC2152868I2 (enExample)
LU (1) LUC00133I2 (enExample)
MX (1) MX2009012453A (enExample)
MY (1) MY151413A (enExample)
NL (1) NL301011I2 (enExample)
NO (1) NO2019037I1 (enExample)
PE (1) PE20090315A1 (enExample)
PL (1) PL2152868T3 (enExample)
PT (1) PT2152868E (enExample)
SI (1) SI2152868T1 (enExample)
TW (1) TWI418633B (enExample)
WO (1) WO2008153776A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US20110201022A1 (en) * 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
EP2531209B1 (en) 2010-02-04 2016-04-20 BioMarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
CA2880620A1 (en) * 2012-07-27 2014-01-30 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
SG11201508598YA (en) * 2013-04-18 2015-11-27 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
WO2015153102A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
DK3145536T3 (da) 2014-04-16 2022-01-03 Codexis Inc Modificeret tyrosinammoniaklyase
KR102438885B1 (ko) 2014-12-22 2022-09-01 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
IL263801B2 (en) 2016-07-26 2024-01-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
JP7024951B2 (ja) * 2016-08-30 2022-02-24 三菱ケミカル株式会社 変異型酵素の製造方法及び変異型アルコールアシルトランスフェラーゼ
CN106497905A (zh) * 2016-12-14 2017-03-15 江南大学 一株鱼腥藻来源的苯丙氨酸脱氨酶的突变体
NZ755628A (en) * 2017-02-13 2023-09-29 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
CN107653275A (zh) * 2017-10-30 2018-02-02 安徽工程大学 D‑苯丙氨酸的制备方法
CN108004225B (zh) * 2017-12-19 2020-05-08 江南大学 一种成团泛菌来源的苯丙氨酸氨基变位酶的突变体
WO2019217513A2 (en) 2018-05-09 2019-11-14 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US10900055B2 (en) * 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
CA3105916A1 (en) * 2018-07-12 2020-01-16 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US11473077B2 (en) 2018-12-14 2022-10-18 Codexis, Inc. Engineered tyrosine ammonia lyase
CN113544268A (zh) 2018-12-20 2021-10-22 科德克希思公司 人类α半乳糖苷酶变体
CN110456056A (zh) * 2019-07-22 2019-11-15 浙江大学 一种新生儿苯丙酮尿症无创筛查试纸的制备方法
US11987823B2 (en) 2019-08-30 2024-05-21 Societe Des Produits Nestle S.A. Engineered lipase variants
WO2021127457A1 (en) 2019-12-20 2021-06-24 Codexis, Inc. Engineered acid alpha-glucosidase variants
CA3168922A1 (en) 2020-02-04 2021-08-12 Codexis, Inc. Engineered leucine decarboxylases
US20230183712A1 (en) * 2020-02-19 2023-06-15 Trustees Of Tufts College Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用ａａｖ及治療調配物之苯酮尿症治療
JP2023539632A (ja) 2020-08-28 2023-09-15 コデクシス， インコーポレイテッド 操作されたプロテアーゼバリアント
MX2023002421A (es) 2020-08-28 2023-05-18 Codexis Inc Variantes de amilasa modificadas geneticamente.
US11918633B2 (en) 2021-05-19 2024-03-05 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
AU2022279241A1 (en) 2021-05-21 2023-11-30 Codexis, Inc. Engineered methionine gamma lyase variants
US20250000957A1 (en) * 2021-09-16 2025-01-02 Arcturus Therapeutics, Inc. Compositions and methods for treating phenylketonuria
CN117417925A (zh) * 2022-07-18 2024-01-19 浙江泽科塔生物医药有限公司 Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
CN116478975B (zh) * 2023-06-16 2023-09-01 苏州优信合生技术有限公司 高活性苯丙氨酸解氨酶突变体及其表达菌株
US20250161466A1 (en) 2023-11-17 2025-05-22 Biomarin Pharmaceutical Inc. Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
PT668933E (pt) 1992-11-19 2003-02-28 Anticancer Inc Utilizacao de metioninase como agente anti-tumor em qimioterapia anti-metionina
ATE361984T1 (de) 1992-12-04 2007-06-15 Me Medical Enzymes Ag Gentechnologisch hergestellte glutaminase und ihre verwendung in therapie
DK75593D0 (enExample) 1993-06-25 1993-06-25 Novo Nordisk As
EP0776218A2 (en) * 1994-03-15 1997-06-04 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
DE851925T1 (de) 1995-09-21 2003-08-14 Genentech Inc., San Francisco Varianten des menschlichen wachstumshormons
CU22585A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
CA2315944A1 (en) * 1997-12-24 1999-07-08 Diatech Pty. Ltd. Bifunctional molecules
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
CA2328614C (en) 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
DE60021760T2 (de) * 1999-12-09 2006-06-08 Chiron Corp., Emeryville Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001257032A1 (en) 2000-04-14 2001-10-30 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6967097B2 (en) 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
WO2002008293A2 (en) * 2000-07-25 2002-01-31 Immunomedics Inc. Multivalent target binding protein
AU2001294774A1 (en) * 2000-09-26 2002-04-08 The Regents Of The University Of California Characterization of phenylalanine ammonia-lyase (pal) gene in wounded lettuce
WO2002038609A2 (en) * 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
WO2003072743A2 (en) 2002-02-26 2003-09-04 E.I. Du Pont De Nemours And Company Method for the recombination of genetic elements
RU2324704C2 (ru) * 2002-07-17 2008-05-20 Цитос Байотекнолоджи Аг Молекулярные массивы антигенов
EP1576127A4 (en) 2002-11-14 2006-10-25 Scripps Research Inst CRYSTAL FORM OF FATTY ACID AMINE HYDROLASE (FAAH)
EP1636266A2 (en) * 2003-06-11 2006-03-22 Wyeth a Corporation of the State of Delaware Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7553653B2 (en) 2004-09-17 2009-06-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Also Published As

Publication number Publication date
LUC00133I2 (enExample) 2020-07-16
LTPA2019517I1 (lt) 2019-10-25
EP2657335A1 (en) 2013-10-30
SI2152868T1 (sl) 2015-12-31
EP2152868B1 (en) 2015-09-02
MY151413A (en) 2014-05-30
MX2009012453A (es) 2010-01-25
IL202132A0 (en) 2010-06-16
EA018443B1 (ru) 2013-08-30
HRP20151268T1 (hr) 2015-12-18
WO2008153776A8 (en) 2009-07-30
WO2008153776A1 (en) 2008-12-18
TWI418633B (zh) 2013-12-11
AU2008263190B2 (en) 2014-04-17
CY2019039I1 (el) 2020-05-29
HUE025784T2 (en) 2016-05-30
JP2010529835A (ja) 2010-09-02
EA200970980A1 (ru) 2010-04-30
AR110834A2 (es) 2019-05-08
KR20150038753A (ko) 2015-04-08
TW200902052A (en) 2009-01-16
US7534595B2 (en) 2009-05-19
LUC00133I1 (enExample) 2019-10-16
CA2687450A1 (en) 2008-12-18
CY1116894T1 (el) 2017-04-05
BRPI0811267B1 (pt) 2020-11-10
CL2008001497A1 (es) 2009-01-09
ES2551315T3 (es) 2015-11-18
AR066716A1 (es) 2009-09-09
BRPI0811267B8 (pt) 2021-05-25
IL202132A (en) 2017-06-29
PL2152868T3 (pl) 2016-01-29
JP5670183B2 (ja) 2015-02-18
CN101842482A (zh) 2010-09-22
KR101603796B1 (ko) 2016-03-17
HK1135141A1 (zh) 2010-05-28
NO2019037I1 (no) 2019-10-16
CY2019039I2 (el) 2020-05-29
NL301011I2 (nl) 2020-05-13
BRPI0811267A2 (pt) 2014-10-07
CN101842482B (zh) 2014-10-22
US20080008695A1 (en) 2008-01-10
EP2152868A1 (en) 2010-02-17
KR20100024437A (ko) 2010-03-05
NL301011I1 (nl) 2019-10-16
CA2687450C (en) 2019-03-26
PT2152868E (pt) 2015-11-13
PE20090315A1 (es) 2009-03-19
AU2008263190A1 (en) 2008-12-18
HUS1900049I1 (hu) 2019-11-28
DK2152868T3 (en) 2015-11-16

Similar Documents

Publication Publication Date Title
LTC2152868I2 (lt) Prokariotinės fenilalanino amonio liazės kompozicijos ir minėtų kompozicijų naudojimo būdai
IL257437B (en) Compositions of prokaryotic phenylalanine ammonia lyase variants and methods of using the compositions
LTPA2019003I1 (lt) Nauji junginiai ir kompozicijos ir jų panaudojimo būdai
LTPA2019006I1 (lt) Junginiai ir kompozicijos kaip proteinkinazės inhibitoriai
BRPI0820298A2 (pt) anticorpos anti-vegf composições e métodos
HRP20170347T1 (hr) Pripravci i postupci za uporabu za protutijela protiv sklerostina
LT2459715T (lt) Rekombinantinio adamts13 ir kitų baltymų gryninimo būdas ir jų kompozicijos
IL204111A (en) Preparations of notch fusion proteins are individualized and used
EP2483362A4 (en) Fluoropropene compounds and compositions and methods using same
EP2296879A4 (en) POLYMER MIXTURES AND METHOD FOR THEIR USE
BRPI0818003A2 (pt) inibidores de csf-1r, composições e métodos de uso
EP2104513A4 (en) OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE
EP2086318A4 (en) NEUROPROTECTIVE COMPOSITIONS AND CORRESPONDING METHODS
BRPI0812159A2 (pt) inibidores de csf-1r, composições e métodos de uso
EP2285405A4 (en) VACCINE COMPOSITIONS AND METHODS
IL196920A0 (en) Compositions and methods using anti-csi antibodies to treat multiple myeloma
DE602008003698D1 (de) Globaler nagelschraubenhaltender Schraubendreher
EP2142926A4 (en) COMPOSITIONS AND METHODS OF DETECTION
IL207827A0 (en) Apoaequorin-containing compositions and methods of using same
GB0605247D0 (en) Compositions and methods for immunisation
DE602007001998D1 (de) Tonerzusammensetzungen und Verfahren
SI2068930T1 (sl) Sestavki in postopki, pri katerih se uporabljajo anti-CS1 protitelesa za zdravljenje multiplega mieloma
BRPI0922033A2 (pt) composições e métodos de uso de variantes de trombomodulina
EP2024461A4 (en) Self-Hydrogenating, Self-Crosslinking Guar Compositions and Methods
ZA200806601B (en) Cryoprotective compositions and methods of using same